Cochrane · systematic review · CD014739
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
Kahale, LA, Matar, CF, Tsolakian, IG, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
34
current version
GRADE rated
24
No studies
10
Included studies
NR
No studies 10 · 29.4%Ungraded 0 · 0%Very low 24 · 70.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aspirin (ASA) compared to vitamin K antagonist (VKA) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 3 [0.12, 73.24] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 0.57 [0.24, 1.33] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 1 [0.25, 3.95] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 7 [0.36, 134.72] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Minor bleeding Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 6 [0.73, 49.43] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Aspirin (ASA) compared to vitamin K antagonist (VKA) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 2 years follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 0.5 [0.05, 5.47] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 0.71 [0.35, 1.44] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Aspirin (ASA) vs vitamin K antagonist (VKA) | RR 1 [0.25, 3.95] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding ‐ not reported Aspirin (ASA) vs vitamin K antagonist (VKA) | no estimate extracted | NR | No studies |
Minor bleeding ‐ not reported Aspirin (ASA) vs vitamin K antagonist (VKA) | no estimate extracted | NR | No studies |
Aspirin (ASA) compared to low molecular weight heparin (LMWH) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 1 [0.06, 15.81] | 2 studies · 781 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 1.23 [0.49, 3.08] | 2 studies · 781 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 7.71 [0.97, 61.44] | 2 studies · 781 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 6.97 [0.36, 134.11] | 2 studies · 781 participants | Very low Downgraded: risk of bias, imprecision |
Minor bleeding Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 1.42 [0.35, 5.78] | 2 studies · 781 participants | Very low Downgraded: risk of bias, imprecision |
Aspirin (ASA) compared to low molecular weight heparin (LMWH) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 2 years follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 1 [0.06, 15.89] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 1.2 [0.53, 2.72] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Aspirin (ASA) vs low molecular weight heparin (LMWH) | RR 9 [0.49, 166.17] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding ‐ not reported Aspirin (ASA) vs low molecular weight heparin (LMWH) | no estimate extracted | NR | No studies |
Minor bleeding ‐ not reported Aspirin (ASA) vs low molecular weight heparin (LMWH) | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) compared to low molecular weight heparin (LMWH) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 0.33 [0.01, 8.1] | 1 study · 439 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 2.32 [0.91, 5.93] | 1 study · 439 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 8.96 [0.49, 165.42] | 1 study · 439 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding ‐ not reported Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | no estimate extracted | NR | No studies |
Minor bleeding Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 0.33 [0.03, 3.17] | 1 study · 439 participants | Very low Downgraded: risk of bias, imprecision |
Vitamin K antagonist (VKA) compared to low molecular weight heparin (LMWH) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 2 years follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 2 [0.18, 21.9] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Symptomatic deep vein thrombosis Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 1.7 [0.8, 3.63] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | RR 9 [0.49, 166.17] | 1 study · 440 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding ‐ not reported Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | no estimate extracted | NR | No studies |
Minor bleeding ‐ not reported Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) | no estimate extracted | NR | No studies |
Aspirin (ASA) compared to direct oral anticoagulants (DOAC) for ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up
Population: ambulatory patients with multiple myeloma receiving immunomodulatory agents
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ not reported Aspirin (ASA) vs direct oral anticoagulants (DOAC) | no estimate extracted | NR | No studies |
Symptomatic deep vein thrombosis ‐ not reported Aspirin (ASA) vs direct oral anticoagulants (DOAC) | no estimate extracted | NR | No studies |
Major bleeding ‐ not reported Aspirin (ASA) vs direct oral anticoagulants (DOAC) | no estimate extracted | NR | No studies |
Minor bleeding Aspirin (ASA) vs direct oral anticoagulants (DOAC) | RR 5 [0.31, 79.94] | 1 study · 8 participants | Very low Downgraded: risk of bias, imprecision |